Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Molecular Templates Inc (MTEM)

Molecular Templates Inc (MTEM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,281
  • Shares Outstanding, K 56,352
  • Annual Sales, $ 38,700 K
  • Annual Income, $ -83,010 K
  • 60-Month Beta 1.18
  • Price/Sales 0.88
  • Price/Cash Flow N/A
  • Price/Book 8.24
Trade MTEM with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.44
  • Most Recent Earnings -0.44 on 11/10/22
  • Next Earnings Date 11/21/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 850.27% ( +270.72%)
  • Historical Volatility 89.26%
  • IV Percentile 97%
  • IV Rank 83.74%
  • IV High 1,008.13% on 11/03/22
  • IV Low 37.29% on 12/27/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 144

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.29
  • Number of Estimates 4
  • High Estimate -0.25
  • Low Estimate -0.42
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -61.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5400 +9.37%
on 11/10/22
0.6810 -13.27%
on 11/01/22
-0.0159 (-2.62%)
since 10/25/22
3-Month
0.5400 +9.37%
on 11/10/22
0.8800 -32.89%
on 09/09/22
-0.2151 (-26.70%)
since 08/25/22
52-Week
0.5400 +9.37%
on 11/10/22
4.5800 -87.10%
on 12/01/21
-3.7094 (-86.27%)
since 11/24/21

Most Recent Stories

More News
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

MTEM : 0.5906 (-2.70%)
PLXP : 0.3500 (-2.91%)
Acutus Medical, Inc. (AFIB) Reports Q3 Loss, Tops Revenue Estimates

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 13.25% and 3.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

AFIB : 0.7000 (+2.94%)
MTEM : 0.5906 (-2.70%)
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 7.69% and 0.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

STVN : 14.90 (-0.67%)
MTEM : 0.5906 (-2.70%)
Ardelyx (ARDX) Reports Q3 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 86.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ARDX : 1.8400 (+3.95%)
MTEM : 0.5906 (-2.70%)
Field Trip Health Ltd. (FTRP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Field Trip Health Ltd. (FTRP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FTRP : 4.2105 (+1.07%)
MTEM : 0.5906 (-2.70%)
Molecular Templates Inc. (MTEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Molecular Templates Inc. (MTEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MTEM : 0.5906 (-2.70%)
DERM : 1.7400 (+2.35%)
Molecular Templates to Present at Upcoming Investor Conferences

AUSTIN, Texas, May 17, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

MTEM : 0.5906 (-2.70%)
Molecular Templates, Inc. Reports First Quarter 2022 Financial Results

AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

MTEM : 0.5906 (-2.70%)
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CPRX : 16.97 (-0.35%)
MTEM : 0.5906 (-2.70%)
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

NKTR : 3.24 (-1.22%)
MTEM : 0.5906 (-2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.6576
2nd Resistance Point 0.6442
1st Resistance Point 0.6174
Last Price 0.5906
1st Support Level 0.5772
2nd Support Level 0.5638
3rd Support Level 0.5370

See More

52-Week High 4.5800
Fibonacci 61.8% 3.0367
Fibonacci 50% 2.5600
Fibonacci 38.2% 2.0833
Last Price 0.5906
52-Week Low 0.5400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar